La vendita allo scoperto per Electromed dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Electromed. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Electromed (AMEX:ELMD) Azioni, Report sulle vendite allo scoperto

Electromed

Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.

Electromed Inc

News

Rumors

Analyst Ratings

Trading Ideas

ELMD

Watching Electromed; Traders Circulate Stock Picked On Popular Retail Stock Trading Newsletter

Buybacks

Electromed Authorized Repurchase Of Up To $5M Of Outstanding Common Stock

WIIM

Electromed shares are trading lower after the company reported worse-than-expected Q4 revenue results.

Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.14 by 42.86 percent. This is a 66.67 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $14.832 million which missed the analyst consensus estimate of $15.000 million by 1.12 percent. This is a 8.96 percent increase over sales of $13.612 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Electromed Q4 2024 GAAP EPS $0.20 Beats $0.14 Estimate, Sales $14.832M Miss $15.000M Estimate

Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.13 by 30.77 percent. This is a 41.67 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $13.87 million which beat the analyst consensus estimate of $13.80 million by 0.51 percent. This is a 14.94 percent increase over sales of $12.07 million the same period last year.

Electromed Q3 EPS $0.17 Beats $0.13 Estimate, Sales $13.87M Beat $13.80M Estimate

<h3>Gainers</h3>
<ul>
<li>Cogent Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) stock increased by 64.0% to $8.96 during Wednesday's regular session. The company's market cap stands at $771.2 million. </li>
<li>Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) shares increased by 45.53% to $12.72. The company's market cap stands at $558.4 million. </li>
<li>BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) stock rose 35.2% to $3.33. The company's market cap stands at $101.0 million. </li>
<li>Greenwich LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLSI#NASDAQ">GLSI</a>) stock moved upwards by 31.26% to $10.91. The company's market cap stands at $140.1 million. </li>
<li>Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) stock rose 22.61% to $12.43. The market value of their outstanding shares is at $106.6 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) shares moved upwards by 18.76% to $7.38. The market value of their outstanding shares is at $350.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock declined by 71.3% to $0.25 during Wednesday's regular session. The market value of their outstanding shares is at $3.0 million. </li>
<li>QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) stock fell 29.1% to $47.34. The company's market cap stands at $3.1 billion. As per the news, the Q4 earnings report came out yesterday. </li>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) shares decreased by 16.35% to $1.18. The company's market cap stands at $30.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares fell 14.9% to $1.2. The company's market cap stands at $59.9 million. </li>
<li>Sientra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEN#NASDAQ">SIEN</a>) shares declined by 14.22% to $0.17. The company's market cap stands at $2.0 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares declined by 12.51% to $0.06. The company's market cap stands at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AZTR

BTAI

COGT

GLSI

Larimar Therapeutics, Inc. - Common Stock

LRMR

NMTC

PBYI

QDEL

RNLX

SBFM

SIEN

12 Health Care Stocks Moving In Wednesday's Intraday Session

Electromed shares are trading higher after the company reported better-than-expected Q2 results.

Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) reported its Q2 earnings results on Tuesday, February 13, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Electromed beat estimated earnings by 90.0%, reporting an EPS of $0.19 versus an estimate of $0.1.
Revenue was up $1.96 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.08 which was followed by a 2.09% increase in the share price the next day.
Here's a look at Electromed's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.10</td>
<td></td>
<td>0.10</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.02</td>
<td>0.12</td>
<td>0.12</td>
<td>0.11</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>12.60M</td>
<td>12.80M</td>
<td>12.05M</td>
<td>11.05M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>12.32M</td>
<td>13.61M</td>
<td>12.07M</td>
<td>11.73M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Electromed <a href="https://www.benzinga.com/quote/ELMD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Electromed Q2 Earnings

Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.10 by 90 percent. This is a 72.73 percent increase over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $13.69 million which beat the analyst consensus estimate of $13.30 million by 2.92 percent. This is a 16.71 percent increase over sales of $11.73 million the same period last year.

Electromed Q2 Gaap EPS $0.19 Beats $0.10 Estimate, Sales $13.69M Beat $13.30M Estimate

ABNB

AKAM

AKTS

ALSN

ANGI

ATOM

BENF

BFAM

BIIB

BRKR

CART

CHCT

CRSR

CTHR

DDOG

DENN

DNUT

ENTG

FELE

GCMG

GDDY

GNSS

GORO

HOOD

HYLN

INCY

INMD

INVH

IOSP

IPGP

KTOS

LCII

LDOS

LOPE

LYFT

MODG

NTWK

REZI

ROIV

RUSHA

RUSHB

SHOP

SITC

SITM

SMWB

SSNC

STAG

TYGO

UFCS

UPST

USAC

VTGN

Earnings Scheduled For February 13, 2024

Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-02-13. Here's what investors need to know before the announcement.
Analysts estimate that Electromed will report an earnings per share (EPS) of $0.10. 
Electromed bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.08, which was followed by a 2.09% increase in the share price the next day.
Here's a look at Electromed's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.10</td>
<td></td>
<td>0.10</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.02</td>
<td>0.12</td>
<td>0.12</td>
<td>0.11</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.09%</td>
<td>10.59%</td>
<td>12.02%</td>
<td>5.68%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Electromed were trading at $10.38 as of February 09. Over the last 52-week period, shares are down 10.97%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ELMD/earnings">To track all earnings releases for Electromed visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Electromed

Biotech

Contracts

General

Electromed  Entered Into Distribution Agreement With Marathon Medical Corp; Financial Terms Not Disclosed

Bradley Nagel, Chief Financial Officer at Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>), reported a large acquisition of company stock options on November 14, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001488917/000143774923032054//Archives/edgar/data/1488917/000143774923032054/0001437749-23-032054-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Nagel, Chief Financial Officer at Electromed, a company in the Health Care sector, was just awarded stock options worth 6,500 shares of ELMD. The options give Nagel the right to buy the company's stock at $10.25 per share.
Electromed shares are trading down 0.0% at $10.52 at the time of this writing on Wednesday morning. Since the current price is $10.52, this makes Nagel's 6,500 shares worth $68,380.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001488917">Check Out The Full List Of Electromed's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Chief Financial Officer at Electromed Acquires Company Stock Options Worth 6,500 Shares

Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.10 by 80 percent. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $12.32 million which missed the analyst consensus estimate of $12.60 million by 2.19 percent. This is a 15.63 percent increase over sales of $10.66 million the same period last year.

Electromed Q1 2024 EPS $0.02 Misses $0.10 Estimate, Sales $12.32M Miss $12.60M Estimate

Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) reported quarterly earnings of $0.12 per share. This is a 200 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $13.60 million which beat the analyst consensus estimate of $12.80 million by 6.25 percent. This is a 20.70 percent increase over sales of $11.27 million the same period last year.

Electromed Q4 EPS $0.12 Up From $0.04 YoY, Sales $13.60M Beat $12.80M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; BHP Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) is estimated to report earnings for its Fiscal Year 2023.
&bull; Dick&#39;s Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) is likely to report quarterly earnings at $3.81 per share on revenue of $3.23 billion.
&bull; Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) is likely to report quarterly earnings at $2.32 per share on revenue of $4.57 billion.
&bull; MINISO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $434.37 million.
&bull; ScanSource (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCSC#NASDAQ">SCSC</a>) is projected to report quarterly earnings at $0.75 per share on revenue of $897.20 million.
&bull; Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) is estimated to report quarterly loss at $0.59 per share on revenue of $129.21 million.
&bull; GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) is likely to report quarterly loss at $0.26 per share on revenue of $337.64 million.
&bull; Macy&#39;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) is estimated to report quarterly earnings at $0.13 per share on revenue of $5.09 billion.
&bull; Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) is estimated to report quarterly loss at $0.97 per share on revenue of $165.57 million.
&bull; BJ&#39;s Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) is projected to report quarterly earnings at $0.90 per share on revenue of $5.15 billion.
&bull; Coty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $1.31 billion.
&bull; Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) is estimated to report quarterly earnings at $0.66 per share on revenue of $356.32 million.
&bull; Kingsoft Cloud Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $268.15 million.
&bull; Canadian Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) is estimated to report quarterly earnings at $1.52 per share on revenue of $2.48 billion.
&bull; Lowe&#39;s Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) is estimated to report quarterly earnings at $4.49 per share on revenue of $24.99 billion.
&bull; Yatsen Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YSG#NYSE">YSG</a>) is estimated to report earnings for its second quarter.
&bull; iQIYI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $1.07 billion.
&bull; Viomi Technology Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIOT#NASDAQ">VIOT</a>) is projected to report earnings for its first quarter.
&bull; BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) is likely to report earnings for its second quarter.
&bull; Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) is expected to report quarterly earnings at $1.11 per share on revenue of $7.57 billion.
&bull; Garmin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) is estimated to report earnings for its second quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Fidelis Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIHL#NYSE">FIHL</a>) is likely to report earnings for its second quarter.
&bull; Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) is likely to report quarterly earnings at $2.81 per share on revenue of $2.41 billion.
&bull; BM Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMTX#AMEX">BMTX</a>) is likely to report quarterly loss at $0.24 per share on revenue of $15.06 million.
&bull; La-Z-Boy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZB#NYSE">LZB</a>) is projected to report quarterly earnings at $0.55 per share on revenue of $474.58 million.
&bull; Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) is likely to report earnings for its fourth quarter.
&bull; Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) is expected to report quarterly earnings at $0.89 per share on revenue of $1.25 billion.
&bull; ToughBuilt Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLT#NASDAQ">TBLT</a>) is likely to report earnings for its second quarter.
&bull; FS Credit Opp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSCO#NYSE">FSCO</a>) is expected to report earnings for its second quarter.
&bull; Complete Solaria (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) is expected to report earnings for its second quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

BIDU

BMTX

BOSC

COTY

CSIQ

CSLR

CTRN

FIHL

FSCO

GRMN

MNSO

PINC

SCSC

SPHR

TBLT

URBN

VIOT

Earnings Scheduled For August 22, 2023

Bradley Nagel, Chief Financial Officer at Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>), reported a large acquisition of company stock options on July 5, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001488917/000143774923019427//Archives/edgar/data/1488917/000143774923019427/0001437749-23-019427-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Nagel, Chief Financial Officer at Electromed, a company in the Health Care sector, was just awarded stock options worth 7,900 shares of ELMD. The options give Nagel the right to buy the company's stock at $10.71 per share.
Electromed shares are trading up 0.09% at $10.61 at the time of this writing on Thursday morning. Since the current price is $10.61, this makes Nagel's 7,900 shares worth $83,819.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001488917">Check Out The Full List Of Electromed's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chief Financial Officer at Electromed Acquires Company Stock Options Worth 7,900 Shares

Management

Electromed Names Jim Cunniff As President and CEO; Succeeding Kathleen Skarvan July 1

EF Hutton analyst Constantine Davides reiterates Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) with a Buy and maintains $15 price target.

Price Target

Reiteration

EF Hutton Reiterates Buy on Electromed, Maintains $15 Price Target

Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) reported its Q3 earnings results on Tuesday, May 9, 2023 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Electromed beat estimated earnings by 20.0%, reporting an EPS of $0.12 versus an estimate of $0.1.
Revenue was up $1.93 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.08 which was followed by a 5.68% increase in the share price the next day.
Here's a look at Electromed's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.03</td>
<td>0.03</td>
<td>0.08</td>
<td>0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.11</td>
<td>0.01</td>
<td>0.04</td>
<td>0.07</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>11.05M</td>
<td>10.70M</td>
<td>10.60M</td>
<td>10.19M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>11.73M</td>
<td>10.66M</td>
<td>11.27M</td>
<td>10.14M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Electromed <a href="https://www.benzinga.com/quote/ELMD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Electromed Q3 Earnings

The MedTech sector's promising future is driven by technological advances, unceasing demand for medical treatments due to an aging population, and increasing global incidence of diseases. To that end, strong MedTech stocks such as Tactile Systems Technology (TCMD), Electromed (ELMD), and Embecta (EMBC) could be wise portfolio additions in July. Read more... The medical industry is set for strong growth due to an aging population, rising infectious diseases, and increasing chronic conditions. With this, the industry's focus on personalized medicine and technological advancements boosts demand for high-quality MedTech products globally, positioning the industry for robust expansion.
Amid this backdrop, it could be wise to add fundamentally strong MedTech stocks such as Tactile Systems Technology, Inc. (<a href="https://stocknews.com/stock/TCMD/">TCMD</a>), Electromed, Inc. (<a href="https://stocknews.com/stock/ELMD/">ELMD</a>), and Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>) to one's portfolio in July.
The MedTech industry's prospects are promising thanks to quality patient care with telemedicine, digital therapeutics, bioprinting, biometric wearables, and the ever-evolving Internet of Medical Things (IoMT). These advancements have led to better patient outcomes and overall industry growth. Hence, the global medical devices market is expected to reach <a href="https://www.fortunebusinessinsights.com/industry-reports/medical-devices-market-100085">$886.80 billion by 2032</a>, growing at a CAGR of 6.3%.
Notably, AI in MedTech has revolutionized the efficient handling of large healthcare data and enabled accurate diagnosis through AI-based image analysis. This enhances cancer detection, tissue assessment, anatomical measurement, and surgical planning, ensuring better patient outcomes. The global AI in medical devices market is expected to reach $97.07 billion by 2028, growing at a <a href="https://blog.marketresearch.com/artificial-intelligence-in-medical-devices-market-set-for-unprecedented-growth">44.4% CAGR</a>.
Considering these conducive trends, let's analyze the fundamentals of the three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> picks mentioned above, beginning with the third choice.
Stock #3: Tactile Systems Technology, Inc. (<a href="https://stocknews.com/stock/TCMD/">TCMD</a>)
TCMD is a medical technology company that develops and provides medical devices to treat underserved chronic diseases. It offers the Flexitouch Plus system and the Entre Plus System. The company also provides Kylee, a mobile application to help patients learn about lymphedema, and AffloVest.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda-margin.asp">EBITDA margin</a>, TCMD's 8.06% is 39.5% higher than the 5.78% industry average. Likewise, its 1.01x trailing-12-month asset turnover ratio is 151.3% higher than the 0.40x industry average. Its 5.69% trailing-12-month EBIT margin is 201% higher than the 1.89% industry average.
During the first quarter that ended March 31, 2024, TCMD's total revenue increased 3.8% year-over-year to $61.09 million. Its non-GAAP gross profit rose 4.7% over the prior-year quarter to $43.75 million. Similarly, its adjusted EBITDA was $1.03 million, up 104.2% over the prior-year quarter.
Moreover, for the three months that ended March 31, 2024, TCMD's cash and cash equivalents – end of period stood at $60.71 million, up 21.3% from the prior-year period.
Street expects TCMD's EPS and revenue for the quarter ended June 30, 2024, to increase 202% and 6.5% year-over-year to $0.14 and $72.81 million, respectively. It surpassed Street revenue estimates in three of the trailing four quarters. Over the past nine months, the stock has gained 13.9% to close the last trading session at $12.75.
TCMD's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect strong prospects. It has an overall rating of B, translating to a Buy in our proprietary system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It is ranked #7 out of 133 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry. It has an A grade for Value and a B for Growth and Quality. <a href="https://stocknews.com/stock/TCMD/">Click here</a> to see TCMD's ratings for Momentum, Stability, and Sentiment.
Stock #2: Electromed, Inc. (<a href="https://stocknews.com/stock/ELMD/">ELMD</a>)
ELMD develops, manufactures, markets, and sells airway clearance therapy and related products that apply high-frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages internationally. The company offers the SmartVest airway clearance system, SmartVest SQL System, and SmartVest Connect.
In terms of the trailing-12-month EBIT margin, ELMD's 10.73% is 467.4% higher than the 1.89% industry average. Likewise, its 1.17x trailing-12-month asset turnover ratio is 190% higher than the 0.40x industry average. Moreover, its 7.0% trailing-12-month levered FCF margin is 448.9% higher than the 1.28% industry average.
ELMD's net revenues for the third quarter that ended March 31, 2024, increased 14.9% year-over-year to $13.87 million. Its operating income came in at $1.84 million, up 53.9% year-over-year. Moreover, the company's net income and net income per share rose 38.9% and 41.7% year-over-year to $1.49 million and $0.17, respectively.
For the quarter ended June 30, 2024, ELMD's EPS and revenue are expected to increase 16.7% and 10.2% year-over-year to $0.14 and $15 million, respectively. Over the past nine months, ELMD's stock has gained 45.4% to close the last trading session at $15.34.
ELMD's positive outlook is reflected in its POWR Ratings. It has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
It has an A grade for Sentiment and a B for Value and Quality. It is ranked #2 in the same industry. <a href="https://stocknews.com/stock/ELMD/">Click here</a> to see ELMD's Growth, Momentum, and Stability ratings.
Stock #1: Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>)
EMBC is a medical device company that focuses on providing various solutions to enhance the health and well-being of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people in managing diabetes.
In terms of the trailing-12-month levered FCF margin, EMBC's 3.91% is 204.9% higher than the 1.28% industry average. Likewise, its 65.57% trailing-12-month gross profit margin is 14.5% higher than the 57.25% industry average. Moreover, its 19.69% trailing-12-month EBITDA margin is 240.9% higher than the 5.78% industry average.
For the fiscal second quarter that ended March 31, 2023, EMBC's revenues grew 3.6% year-over-year to $287.20 million, while its adjusted gross profit for the quarter stood at $185.80 million. For the same quarter, the company's adjusted net income and adjusted net income per share came in at $38.90 million and $0.67, respectively.
EMBC's total current liabilities as of March 31, 2024, amounted to $310.40 million, compared to $353.50 million as of September 30, 2023.
Analysts expect EMBC's revenue for the quarter ending December 31, 2024, to increase marginally year-over-year to $277.39 million. EMBC surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past three months, the stock has gained 27.5% to close the last trading session at $13.20.
EMBC's strong fundamentals are reflected in its POWR Ratings. It has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has an A grade for Value and Quality and a B for Growth. Within the Medical - Devices &amp; Equipment industry, it is ranked #first. To see EMBC's Momentum, Stability, and Sentiment rating, <a href="https://stocknews.com/stock/EMBC/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
EMBC shares were trading at $13.56 per share on Wednesday afternoon, up $0.36 (+2.73%). Year-to-date, EMBC has declined -26.78%, versus a 18.12% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/embc-tcmd-elmd-3-medtech-stocks-to-add-to-your-portfolio-in-july/>3 MedTech Stocks to Add to Your Portfolio in July</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 MedTech Stocks to Add to Your Portfolio in July

The latest announcement is out from Electromed (ELMD). Electromed, Inc. has refreshed its investor presentation, which will be utilized in upcoming...

Electromed Updates Investor Presentation for Future Engagements

Electromed GAAP EPS of $0.20 beats by $0.06, revenue of $14.8M

Electromed (ELMD) has provided an announcement. The Company has refreshed its investor presentation, which will be leveraged in upcoming discussion...

Electromed Unveils Updated Investor Presentation Strategy

Electromed, Inc. 2024 Q4 - Results - Earnings Call Presentation

Electromed, Inc. (ELMD) Q4 2024 Earnings Call Transcript

Lake Street Reaffirms Their Buy Rating on Electromed (ELMD)

Electromed authorizes $5M share buyback

Electromed ( ($ELMD) ) just unveiled an announcement. Electromed, Inc. has announced a new share repurchase program authorizing the buyback of up t...

Electromed Signals Growth Confidence With Stock Buyback Plan

Electromed: Pure Player In A Niche Market With Massive Potential

EMBC

TCMD

Press Releases

Electromed, Inc. to Participate in the 2024 Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Electromed, Inc. Schedules its Third Quarter Fiscal 2024 Financial Results Conference Call for May 7, 2024 at 5:00 p.m. ET

Electromed, Inc. Announces Record Revenue in Fiscal 2024 Third Quarter

Electromed, Inc. to Participate in the 2024 Sidoti June Small-Cap Virtual Conference

Electromed, Inc. to Participate in the 2024 Canaccord Global Growth Conference

Electromed, Inc. Schedules its Fourth Quarter Fiscal 2024 Financial Results Conference Call for August 27, 2024 at 5:00 p.m. ET

Electromed, Inc. Announces Record Fiscal Year 2024 Financial Results

Electromed, Inc. Announces Share Repurchase Authorization

Electromed, Inc., Appoints Peter Horwich, Vice President, Marketing

Electromed, Inc. Schedules its First Quarter Fiscal 2025 Financial Results Conference Call for November 12, 2024 at 5:00 p.m. ET

AngioDynamics

Accuray

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

BrainsWay Ltd. - American Depositary Shares

BrainsWay

CVRx

Delcath Systems

Alpha Tau Medical

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Electromed

Vendite allo scoperto

Electromed (AMEX:ELMD) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO